{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:10:16Z","timestamp":1790691016878,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.clml.2026.01.017","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:39:33Z","timestamp":1770424773000},"page":"e631-e635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Progressive Multifocal Leukoencephalopathy (PML) in 2 Patients Treated With Elranatamab"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1059-2906","authenticated-orcid":false,"given":"Oliver","family":"Tomkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5436-8239","authenticated-orcid":false,"given":"Rea Grace","family":"Maamari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Douthwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamish","family":"Bain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Kohli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"de Lavallade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Kazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajitha","family":"Sachchithanantham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Dmello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Gault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Streetly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Warcel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2026.01.017_bib0001","unstructured":"Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (2024).https:\/\/www.nice.org.uk\/guidance\/ta1023 (accessed 23\/02\/2026)"},{"key":"10.1016\/j.clml.2026.01.017_bib0002","unstructured":"Elrexfio (elranatamab) \u2013 Annex I: summary of product characteristics. 2024. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2024\/20241113164235\/anx_164235_en.pdf. (accessed 23\/02\/2026)"},{"issue":"9","key":"10.1016\/j.clml.2026.01.017_bib0003","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.01.017_bib0004","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1182\/blood-2024-208192","article-title":"MagnetisMM-3: long-term update and efficacy and safety of less frequent dosing of elranatamab in patients with relapsed or refractory multiple myeloma","volume":"144","author":"Prince","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.01.017_bib0005","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.clml.2026.01.017_bib0006","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1474-4422(18)30040-1","article-title":"Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned","volume":"17","author":"Major","year":"2018","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.clml.2026.01.017_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/v12090969","article-title":"Fifty years of JC polyomavirus: a brief overview and remaining questions","volume":"12","author":"Atkinson","year":"2020","journal-title":"Viruses"},{"issue":"17","key":"10.1016\/j.clml.2026.01.017_bib0008","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","article-title":"Pembrolizumab treatment for progressive multifocal leukoencephalopathy","volume":"380","author":"Cortese","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2026.01.017_bib0009","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.26512","article-title":"Progressive multifocal leukoencephalopathy treated by immune checkpoint inhibitors","volume":"93","author":"Boumaza","year":"2023","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.clml.2026.01.017_bib0010","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2026.01.017_bib0011","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.3390\/curroncol31050202","article-title":"Progressive multifocal leukoencephalopathy unmasked by teclistamab in a refractory multiple myeloma patient","volume":"31","author":"Arvanitis","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clml.2026.01.017_bib0012","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2025.288521","article-title":"Progressive multifocal leukoencephalopathy and BK virus-nephropathy with bispecific antibody therapy in multiple myeloma","author":"Siegel","year":"2025","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.clml.2026.01.017_bib0013","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1128\/jcm.33.2.484-486.1995","article-title":"Diagnostic value of detecting JC virus DNA in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy","volume":"33","author":"Fong","year":"1995","journal-title":"J Clin Microbiol."},{"issue":"1","key":"10.1016\/j.clml.2026.01.017_bib0014","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","article-title":"Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease","volume":"17","author":"Cortese","year":"2021","journal-title":"Nat Rev Neurol"},{"issue":"15","key":"10.1016\/j.clml.2026.01.017_bib0015","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMoa1801540","article-title":"Allogeneic BK virus\u2013specific T cells for progressive multifocal leukoencephalopathy","volume":"379","author":"Muftuoglu","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2026.01.017_bib0016","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S1474-4422(21)00174-5","article-title":"BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study","volume":"20","author":"Cortese","year":"2021","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.clml.2026.01.017_bib0017","doi-asserted-by":"crossref","DOI":"10.3390\/v17070934","article-title":"Adoptive JC virus-specific T lymphocytes for the treatment of progressive multifocal leukoencephalopathy: experience from two Italian centers","volume":"17","author":"Pocora","year":"2025","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.clml.2026.01.017_bib0018","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/ejh.13909","article-title":"Progressive multifocal leukoencephalopathy in multiple myeloma","volume":"110","author":"Hoeynck","year":"2023","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1016\/j.clml.2026.01.017_bib0019","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.3324\/haematol.2023.283003","article-title":"Protracted viral infections in patients with multiple myeloma receiving bispecific T-cell engager therapy targeting B-cell maturation antigen","volume":"108","author":"Palmen","year":"2023","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.clml.2026.01.017_bib0020","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001042","article-title":"Combined treatment with pembrolizumab and allogenic BK virus-specific T cells in progressive multifocal leukoencephalopathy: a case report","volume":"8","author":"Wicklein","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:38:52Z","timestamp":1778067532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026000315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2152265026000315"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.01.017","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progressive Multifocal Leukoencephalopathy (PML) in 2 Patients Treated With Elranatamab","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}